{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiht64d3svmsstsceu4mnxqfivr6zi7loybswyhwg57rzm2wnatd6a",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mn3o37uycdd2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidejfwognityu6yygyzgf2bvpuieq4dxcyhxugtqdmow7wybv23yu"
    },
    "mimeType": "image/jpeg",
    "size": 258354
  },
  "path": "/news/2026-05-tezepelumab-severe-asthma-patients-oral.html",
  "publishedAt": "2026-05-30T14:00:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "New results from the Phase III SUNRISE clinical trial show that tezepelumab significantly reduced the need for long-term oral corticosteroid use in adults with severe oral corticosteroid-dependent asthma while maintaining asthma control and improving key clinical outcomes. The findings were published in The Lancet Respiratory Medicine.",
  "title": "Tezepelumab helps severe asthma patients reduce oral steroids over 28 weeks"
}